Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.

Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.

<h4>Background & aims</h4>We evaluated the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in difficult-to-treat PWIDs with presumed high risk for non-adherence to antiviral therapy using an innovative concept involving their opioid agonist therapy (OAT) facility.<h4>Methods&...

Full description

Bibliographic Details
Main Authors: Caroline Schmidbauer, Michael Schwarz, Angelika Schütz, Raphael Schubert, Cornelia Schwanke, Enisa Gutic, Roxana Pirker, Tobias Lang, Thomas Reiberger, Hans Haltmayer, Michael Gschwantler
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0252274

Internet

https://doi.org/10.1371/journal.pone.0252274

Similar Items